World's Best Scientists 2026 revealed!
Stacie B. Dusetzina

Stacie B. Dusetzina

D-Index & Metrics

Economics and Finance

D-Index
33
Citations
4513
World Ranking
3288
National Ranking
1776

Best Publications

  • Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia

    Stacie B. Dusetzina;Aaron N. Winn;Gregory A. Abel;Haiden A. Huskamp

  • Impact of FDA drug risk communications on health care utilization and health behaviors: a systematic review.

    Stacie B. Dusetzina;Ashley S. Higashi;E. Ray Dorsey;Rena Conti

  • Financial Toxicity in Adults With Cancer: Adverse Outcomes and Noncompliance

    Thomas G. Knight;Allison M. Deal;Stacie B Dusetzina;Hyman Bernard Muss

  • A Policy Prescription for Reducing Health Disparities-Achieving Pharmacoequity.

    Utibe R Essien;Stacie B Dusetzina;Walid F Gellad

  • Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in chronic phase after generic entry of imatinib in the United States

    William V. Padula;Richard A. Larson;Stacie B. Dusetzina;Jane F. Apperley

  • Drug Pricing Trends for Orally Administered Anticancer Medications Reimbursed by Commercial Health Plans, 2000-2014

    Stacie B. Dusetzina

  • Many Medicare Beneficiaries Do Not Fill High-Price Specialty Drug Prescriptions.

    Unknown

  • Financial Relationships With Industry Among National Comprehensive Cancer Network Guideline Authors

    Aaron P. Mitchell;Ethan M. Basch;Stacie B. Dusetzina

  • Treating depression after initial treatment failure: directly comparing switch and augmenting strategies in STAR*D.

    Bradley N. Gaynes;Stacie B. Dusetzina;Alan R. Ellis;Richard A. Hansen;Richard A. Hansen

  • Specialty Drug Pricing and Out-of-Pocket Spending on Orally Administered Anticancer Drugs in Medicare Part D, 2010 to 2019

    Stacie B. Dusetzina;Haiden A. Huskamp;Nancy L. Keating

  • Trends in Inpatient and Outpatient Hysterectomy and Oophorectomy Rates Among Commercially Insured Women in the United States, 2000-2014.

    Kemi M. Doll;Stacie B. Dusetzina;Whitney Robinson

  • The impact of out-of-pocket costs on the use of intrauterine contraception among women with employer-sponsored insurance.

    Lydia E. Pace;Stacie B. Dusetzina;A. Mark Fendrick;Nancy L. Keating

  • Cost-Related Medication Nonadherence and Desire for Medication Cost Information Among Adults Aged 65 Years and Older in the US in 2022

    Unknown

  • Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance).

    Charles L. Shapiro;James P. Moriarty;Stacie Dusetzina;Andrew L. Himelstein

  • Financial Toxicity of Cancer Treatment

    Unknown

  • Association of Prescription Drug Price Rebates in Medicare Part D With Patient Out-of-Pocket and Federal Spending.

    Stacie B. Dusetzina;Rena M. Conti;Nancy L. Yu;Peter B. Bach

  • Mind the Gap: Why Closing the Doughnut Hole Is Insufficient for Increasing Medicare Beneficiary Access to Oral Chemotherapy

    Stacie B. Dusetzina;Nancy L. Keating

  • Control Outcomes and Exposures for Improving Internal Validity of Nonrandomized Studies

    Stacie B Dusetzina;M Alan Brookhart;Matthew L Maciejewski

  • Pharmaceutical Industry Payments and Oncologists' Selection of Targeted Cancer Therapies in Medicare Beneficiaries.

    Aaron P. Mitchell;Aaron N. Winn;Stacie B. Dusetzina

  • For Uninsured Cancer Patients, Outpatient Charges Can Be Costly, Putting Treatments Out Of Reach

    Stacie B. Dusetzina;Ethan Basch;Nancy L. Keating

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Recently Published Articles